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ABSTRACT
Fanconi Anemia (FA) is a rare genetic disease caused by biallelic mutations in
one of sixteen genes involved in the FA-BRCA DNA damage repair pathway. The
proteins encoded by these genes function cooperatively in a common pathway which
resolves lesions caused by interstrand crosslinks (ICLs). A critical step in this pathway
is the monoubiquitination and chromatin targeting of FANCD2 and FANCI. The
mechanism by which these proteins are targeted to chromatin is not understood.
FANCD2 is known to interact with several downstream proteins while associated with
chromatin. Finding new FANCD2 interacting proteins is critical to understanding how
FANCD2 functions and how it is regulated within the cell. I have identified several
candidate interacting proteins by immunoprecipitations (IPs) coupled with mass
spectrometry. Candidates include transcription factors, chromatin remodeling complex
components and proteins involved in chromosome maintenance and stability. These
interactions are being validated and functionally characterized using a variety of
techniques.
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STATEMENT OF THE PROBLEM

FANCD2 is a critical protein in the FA pathway, which is monoubiquitinated
by the core complex and localized to chromatin. Abrogation of either of
monoubiquitination or chromatin localization results in the defective repair of damage
caused by interstrand crosslinks. Both the regulation and function of FANCD2 are
poorly understood. Identification of novel FANCD2 interacting proteins is critical to
fully understanding the role that FANCD2 plays in the cell. The goal of the project is
to identify novel FANCD2 interaction protein candidates using immunoprecipitation
in tandem with mass spectrometry and then to validate and functionally characterize
these interactions. The hope is that this data may shed light on the biochemical process
in the cell and open new opportunities for patient treatment.

viii

CHAPTER 1

INTRODUCTION

Fanconi Anemia
Fanconi anemia is a rare genetic disease characterized by congenital defects,
genomic instability, and a predisposition to bone marrow failure and cancer (Walden
2014). Biallelic mutations in one of sixteen bona fide FA genes cause this disease.
These gene products act cooperatively in the FA-BRCA pathway to recognize and
repair ICLs within the DNA (Walden 2014). ICLs are highly genotoxic complex
lesions which prevent DNA strand separation required for both replication and
transcription (Deans 2011). The inability to correctly repair these lesions may lead to
replication fork stalling or arrest, deleterious repair, or cell death particularly in white
blood cells (Deans 2011). Most FA patients present anemia and early onset of bone
marrow failure. Hypersensitivity to DNA crosslinking agents is a hallmark of FA
patient cells (Kim 2012). This combination of increased propensity for hematological
abnormalities and cancers, with fewer effective treatment options, makes the
understanding of the molecular pathology critical for development of new treatment
opportunities.

FA Activation
Much work has been done in recent years to help elucidate the mechanistic
action of the FA proteins. The recognition and stabilization of the lesion is
accomplished by FANCM, FAAP24, MHF1, and MHF2, which prevent replication
1

fork collapse (Meetei 2005, Ciccia 2007, Zhijiang 2010). Following lesion recognition
the core complex is recruited which is composed of FANCA, FANCB, FANCC,
FANCE, FANCF, FANCF, FANCG, FANCL, and FANCM. The core complex
monoubiquitinates FANCD2 and FANCI on K561 and K523 respectivly, which leads
to chromatin targeting and the recruitment of downstream DNA repair proteins
(Garcia-Higuera 2001, Sims 2007, Smogorzewska 2007). The monoubiquitination is
seen as a marker of pathway activation. The loss of any core complex member, other
than FANCM, abolishes FANCD2 and FANCI ubiquitination (Bakker 2009).

FANCD2
FANCD2 is an orphan protein which has until recently been largely
uncharacterized. The closest protein to FANCD2 is its paralog FANCI, which together
form a heterodimer known as the ID2 complex. FANCD2 has four recognized
domains, the EDGE, PIP, CUE, and NLS domains (Montes de Oca 2005, Howlett
2009, Rego 2012, Boisvert 2013). FANCD2 has also been implicated in binding
directly to chromatin though the mechanism for this remains unknown. Different
forms of DNA, such as circular dsDNA, dsDNA, fragments and, ssDNA, have been
shown to specifically increase the association between chromatin and FANCD2
(Sareen 2012). It has also been proposed that FANCD2 harbors both nucleosome
chaperone activity and the ability to promote site-specific transcriptional activation
(Sato 2012, Park 2013). Despite these domains being characterized the functional and
mechanistic role of this protein is still largely unknown.

2

FANCD2 Monoubiquitination
The monoubiquitination of FANCD2 and FANCI has been used as a marker
for activation of the FA-BRCA pathway. The monoubiquitination event is key for the
recruitment of FANCD2 and FANCI to chromatin. FANCD2 mutants that harbor a
K561R mutation are not able to become ubiquitinated and do not rescue sensitivity to
crosslinking agents (Garcia-Higuera 2001). The primary function of the FA core
complex is this ubiquitination reaction. The ubiquitination is mediated through the E3
ligase activity of FANCL and UBE2T, an E2 ubiquitin conjugating enzyme specific
for FANCL (Meetei 2003, Machida 2006). This ubiquitination is easily measurable by
western blotting as the ubiquitin conjugation causes a detectable shift in the masses of
FANCD2 and FANCI. FANCB, FANCL and FAAP100 have been shown to form a
subcomplex which is able to ubiquitinate FANCD2 in vitro indicating that the other
core complex members have some other unknown functions which are required for
efficient ubiquitination in vivo (Rajendra 2014). This ubiquitination conjugation is a
reversible reaction using the deubiquitinating enzymes USP1 and UAF1 (Nijman
2005, Cohn 2007).

FA and DNA Repair
The monoubiquitination event of FANCD2 and FANCI leads to the eventual
recruitment of downstream repair proteins. The downstream proteins consist of
FANCD1/BRCA2,

FANCJ/BRIP1,

FANCN/PALB2,

FANCO/RAD51C,

FANCP/SLX4, and FANCQ/XPF. It was originally thought that FANCP/SLX4 and
FAN1 were recruited to the sites of damage through a specific interaction with
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ubiquitinated FANCD2, however it is now known that the nucleases are recruited
through a mechanism independent of FANCD2 monoubiquitination (Kimiyo 2011,
Kim 2011, Shereda 2010, Chaudhury 2014, Lachaud 2014). FANCP/SLX4 acts as a
recruitment platform for the nuclease complexes XPF-ERCC1, MUS81-EME1 as well
as SLX1, which are able to contribute to resolving the complex structure generated by
the ICLs (Zhang 2014). The incisions created by the nucleases are critical for crosslink
unhooking and enabling initiation of translesion synthesis (TLS) as well as double
strand breaks (DSBs) formation (Walden 2014).

TLS and Homologous Recombination
Once the crosslink has been unhooked TLS polymerases are recruited to the
site to bypass the lesion. The TLS polymerases are able to synthesize across the lesion
and allow for resumption of normal replication (Sharma 2013). FANCC has been
shown to promote the recruitment of factors involved in switching to the error prone
TLS replicative mechanism (Niedzwiedz 2004). Once the ICL lesion has been
synthesized over by TLS, the DSBs that were created during nucleotide excision must
be repaired in an error free manner to avoid the loss of genetic material and an
increase in genomic instability. The remaining downstream proteins in the FA-BRCA
pathway FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, and FANCO/RAD51C
promote RAD51 loading onto single stranded DNA. RAD51 is critical to the
homologous recombination (HR) pathway by its ability to coordinate with a
homologous DNA sequence and promote strand invasion (Mazón 2010). This process
prevents the loss of genetic information by using the paired strand as a template for the
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damaged strand ensuring accurate hybridization across the previously damaged region.
FA patients are thought to have difficulty in promoting HR over nonhomologous end
joining (NHEJ) repair which, in contrast, is an error prone mechanism. The
deregulation of this error prone repair pathway has been implicated as a possible cause
for the genomic instability found in FA patients (Adamo 2010, Pace 2010, Bunting
2010). It is important for patient treatment that both the mechanics and regulation of
the FA-BRCA pathway are well understood.

Unbiased Screening for FANCD2 Interactors
The discovery of novel FANCD2-interacting proteins is essential for a more
complete understanding of the role that FANCD2 plays in the cell. Using a variety of
methods FANCD2 has been shown to interact with several proteins including, but not
limited to, FANCI, FANCE, FANCJ/BRIP1, MEN1, CtIP, and the MCM helicase
proteins (Sims 2007, Smogorzewska 2007, Pace 2002, Gordon 2003, Chen 2014, Jin
2003, Murina 2014, Unno 2014, Lossaint 2013). Biochemical based studies have
resulted in a huge increase of the understanding in how FA works. The first six FA
genes were identified through a positional cloning approach (Lo Ten Foe 1996,
Fanconi anaemia/Breast cancer consortium 1996, Strathdee 1992, Timmers 2001, de
Winter 1998, de Winter and Rooimans 2000, de Winter and Léveillé 2000).
Biochemical approaches such as co-immunoprecipitations (co-IPs) have been
instrumental in the discovery of the ten most recently discovered FA genes as well as
several interacting partners (Meetei 2004, Howlett 2002, Dorsman 2007, Levran 2005,
Litman 2005, Levitus 2005, Meetei 2003, Meetei 2005, Xia 2007, Reid 2007, Vaz
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2010, Stoepker 2011, Bogliolo 2013). Identifying interacting networks and partners
such as BRCA and BLM has provided a great deal of understanding about how the
FA-BRCA pathway functions and what it is responsible for within the cell (Howlett
2002, Pichierri 2004). Immunoprecipitation coupled with mass spectrometry is a
proven technique within the FA field, contributing directly to the discovery of
FANCN/PALB2 (Xia 2006). Similar techniques were recently used to identify the
interaction between FANCD2 and the MCM helicases (Lossaint 2013). Using large
scale systems combined with the sensitivity of modern biochemical techniques we
hope to discover novel FANCD2 interacting proteins using an unbiased system.

6

CHAPTER 2

METHODOLOGY

Cell Culture
HeLa cells (human cervical cancer cells, Scherer 1953) were grown in
Dulbecco’s modified Eagle’s medium (DMEM, Gibco11965-092) supplemented with
12% fetal bovine serum (FBS, Gibco 26140-079) 2 mM L-glutamine (Gibco 25030081) 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063). PD20
(FA-D2 patient fibroblasts) cells were purchased from Coriell Cell Repositories
(Catalog ID GM16633).
PD20 cells are a human transformed cell line that have a heterozygous
FANCD2 deficiency as a result of biallelic mutations and lack functional FANCD2.
The maternal allele contains a frameshift mutation resulting in a severe truncation, and
the paternal allele has a missense mutation, causing the cells to express highly
diminished amounts of FANCD2 protein which fail to correct ICL sensitivity
(Timmers 2001). The corrected cells we generated using pLenti6.2-FANCD2 and
pDEST40-FANCD2-V5-6xHis. The pLenti6.2 construct incorporates a V5 epitope tag
on the protein which can be targeted by commercially available antibodies and a
blasticidin resistance so that cells can be cultured in media supplemented with 2µg/mL
blasticidin (Invitrogen R210-01) for selection. The control lines have a stably
incorporated pLenti6.2-LacZ-V5 cultured with 2µg/mL blasticidin (Invitrogen R21001) or, empty pMMP plasmid and is cultured in media supplemented with 1 µg/mL
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puromycin (Sigma Aldrich P-8833). PD20s were grown in DMEM (Gibco11965-092)
supplemented with 15% FBS (Gibco 26140-079) 2 mM L-glutamine (Gibco 25030081) 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063).
MCF10A (nonmalignant epithelial cells, Cohet 2010) cells containing
doxycycline inducible SMARCA2/BRM, SMARCA4/BRG1 (members of the
SWI/SNF complex) and scrambled shRNA cassettes were a generous gift from
Anthony Imbalzano, and Jeffrey Nickerson with help from Karen Imbalzano, and
Jason Dobson. MCF10A cells were cultured in Dulbecco’s modified Eagle’s
medium/nutrient mixture F-12 (DMEM/F-12, Gibco 11330-032) supplemented with
5% horse serum (Gibco 16050-122), 100 mg/mL human epidermal growth factor
(EGF, Peprotech AF-100-15), 1 mg/mL hydrocortizone (Sigma Aldrich H-0888), 1
mg/mL cholera toxin (Sigma Aldrich C-8052), 10 mg/mL insulin (Sigma Aldrich I1882), 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063).
Induction of shRNA expression was achieved by treating with 0.01µg/mL of
doxycycline (Sigma Aldrich D-9891) for 72 hours and confirmed by GFP expression.
Cells were cultured at 37oC with 5% CO2 and subjected to 0.05% trypsin
EDTA dissociation solution (Gibco 25300-054) for maintenance. Cells were treated
with mitomycin C (MMC, Sigma Aldrich M-0503) to induce crosslink formation.

Cellular Fractionation
Cells underwent a subcellular fractionation to enrich for chromatin associated
proteins. Following treatment, cells were collected in 0.05% trypsin EDTA
dissociation solution and DMEM, and pelleted in a centrifuge at 1200xg at 4oC over 4
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minutes. The pellet was resuspended and washed in phosphate buffered saline pH 7.4
(Gibco 10010-023) and pelleted again. Cells were first lysed in ice cold cytoskeletal
(CSK) buffer (10 mM PIPES pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2,
1 mM EGTA, and 0.5% v/v Triton-X-100) for 10 minutes at 4oC. The remaining pellet
was washed once with CSK buffer and subjected to either nuclease reaction buffer
(NRB) (20 mM Tris HCl, 100 mM KCl, 2 mM MgCl2, 1mM CaCl2, 0.3M Sucrose,
0.1% v/v Triton-X-100, Roche protease inhibitor cocktail tablet) or ice cold ATM
lysis buffer (Sun 2009) (20 mM HEPES pH 7.4, 150 mM NaCl, .2% Tween20, 1.5
mM MgCl, 1 mM EGTA, 2 mM DTT, 50 mM NaF, 500 µM Na3O4V, 1 mM PMSF,
Roche protease inhibitor cocktail tablet). The sample was subjected to sonication for
ten seconds at 10% amplitude using a Fisher Scientific Model 500 Ultrasonic
Dismembrator then supplemented with 0.1% v/v micrococcal nuclease (New England
Biolabs M0247S) for twenty minutes at room temperature or 0.05% v/v benzonase
(Sigma Aldrich E-1014) for thirty minutes on ice, respectively. Samples were spun at
16100xg for two minutes and the supernate containing the chromatin associated
proteins were placed in a new ice cold tube. Chromatin fractions were quantified using
the bicinchoninic acid (BCA) assay (PI-23227, Fisher) to allow for normalization.

Antibodies
Mouse monoclonal antibodies used were α-tubulin (MS-581-P1, NeoMarkers),
FANCD2 (sc-20022, Santa Cruz), GFP (sc-9996, Santa Cruz), H4 (L64C1, Cell
Signaling), and V5 (R960-25, Invitrogen).
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Rabbit polyclonal antibodies used were CAPD2 (A300-601A, Bethyl), CAPD3
(A300-604A, Bethyl), FANCD2 (NB100-182, Novus Biologicals), H2A (07-146,
upstate), H3 (ab1791, Abcam), SMC1A (A300-055A, Bethyl), SMC4 (A300-064A,
Bethyl), SMC6 (A300-237A, Bethyl), and VCP (ab109240, Abcam).

Immunoprecipitation
FANCD2 immunoprecipitations were performed with protein G Sepharose
(17-6002-35, GE) or protein G Dynabeads (10003D, Invitrogen). Beads were washed
three times for 5 min in NETN100 (20 mM Tris-HCl, 100mM NaCl, 1 mM EDTA,
1mM Na3O4V, 1 mM NaF, Roche protease inhibitor cocktail tablet) + 1% bovine
serum albumin (BSA) (BP1600-100, Fisher) then once more for 15 min to block the
beads. The beads are washed three times in NETN100 buffer. NETN100 is added to
the chromatin fraction to q.s. the volume up to 1 mL. A portion of the pre-blocked
beads are added to the mixture containing the nuclear fraction for thirty minutes while
nutating at 4oC, to pre-clear any nonspecific interactions from the mixture. Using
gentle centrifugation (or a magnet for Dynabeads) allows the beads to be separated
from the mixture which is removed and placed into a new tube where the FANCD2
antibody is added and allowed to incubate while nutating at 4oC. The beads are added
to the reaction and allowed to incubate for an additional two hours while nutating at
4oC. Gentle centrifugation (or the magnet) is used to sequester the beads at the bottom
of the tube while the unbound supernatent components are aspirated. The beads are
washed four times in NETN100. The beads are eluted with 2x LDS (NP-0008,
NuPage) with 5% v/v β-mercaptoethanol with heating at 95oC for 10 min.
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V5 Agarose Immunoprecipitation
V5 immunoprecipitations were performed with V5 conjugated agarose beads
(ab1229, Abcam). Beads were washed three times for five minutes in NETN100 (20
mM Tris-HCl, 100mM NaCl, 1 mM EDTA, 1mM Na3O4V, 1 mM NaF, Roche
protease inhibitor cocktail tablet) + 1% bovine serum albumin (BSA) (BP1600-100,
Fisher) than once more for fifteen minutes to block the beads. The beads are than
washed three times in NETN100 buffer. Samples were brought up to an equal volume
using the ATM lysis buffer. V5 conjugated beads were added and allowed to incubate
for two hours at 4oC while nutating. Beads were separated from the supernatant by
gentle centrifugation. The supernatant was aspirated and the beads were washed four
times with ice cold NETN100 for five minutes. After the final wash the beads were
aspirated dry using a needle. The beads are eluted into 2x LDS (NP-0008, NuPage)
with 5% β-mercaptoethanol by heating at 95oC for fifteen minutes.

SDS-PAGE
Electrophoresis was accomplished using NuPAGE 3-8% Tris-Acetate and 412% Bis-Tris polyacrylamide gels (EA0378BOX and NP0335BOX, NuPAGE).
Samples were lysed by either CSK buffer, NRB, ATM lysis buffer or in 2% SDS lysis
buffer (SDS) (2% v/v SDS, 50 mM Tris-HCl pH 7.4, 10 mM EDTA). Lysates were
supplemented with 4x LDS (NP-0008, NuPage) to a 1x concentration except for IP
eluates which were run in their 2x elution buffer. Samples were run with the
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Kaleidoscope prestained standard (161-0324, Bio-Rad) for reference as a molecular
weight marker.

Immunoblotting
For immunoblotting analysis proteins were transferred from the SDS-PAGE
matrix onto 0.45µm polyvinylidene difluoride (PVDF) (IPVH00010, Immobilon)
membrane with a semi-dry electrophoretic transfer cell (170-3940, Bio-Rad). Transfer
membranes were rinsed in Tris-buffered saline with Tween 20 (TBST; 0.1% v/v
Tween 20, 150 mM NaCl, 25 mM Tris-HCl, pH 7.6) and subsequently blocked in 5%
w/v dry milk in TBST for one hour at room temperature. Membranes were repeatedly
washed in TBST before being incubated with the primary antibody in TBST overnight
at 4oC or for two hours at room temperature. Horseradish peroxidase conjugated
secondary antibodies against mouse and rabbit IgG (NA931V and NA934V, GE) were
hybridized

to

the

primary

antibodies.

The

complex

was

detected

with

chemiluminescent reagent (170-5060, Bio-Rad or NEL 101, NEL102, Perkin Elmer)
and visualized using a film developer (CP1000, Agfa).

Gel Staining, Tryptic Digestion and Mass Spectrometry
The SDS-PAGE matrix was stained using SimblyBlue SafeStain (LC6060,
Invitrogen) or mass spec compatible silver stain (24600, Thermo). Staining was
performed as described in the respective protocols. Tryptic digestion was performed
using the in-gel tryptic digestion kit (89871, Thermo). Protocol was performed as
described in the manual using TCEP for reduction and Iodoacetamide for alkylation.
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When possible, digestion was performed inside a biosafety cabinet to reduce the
prevalence of keratin contamination. Tryptic digestion was incubated at 30oC
overnight. The supernate was removed and placed into a clean new tube. The
remaining gel pieces were subjected to a secondary extraction using 50% acetonitrile
and 5% formic acid. The secondary extraction was collected and combined with the
primary extraction than stored in the -20oC freezer. Samples were submitted to Dr.
James Clifton at Brown University EPSCoR proteomics facility. Samples were
submitted as low complexity samples to be run through LC coupled MS/MS on the
LTQ Orbitrap Velos mass spectrometer.

Spectral Analysis
Analysis of spectral data was performed in multiple iterations using different
systems. Initial analysis was performed using the MASCOT database which uses a
probability based peptide finger printing method to automatically identify and evaluate
spectral data (Perkins 1999). ProteoIQ v2.2 was used to remove hits that fell below the
5% protein false discover rate threshold. ProteoIQ was used in tandem with manual
curation of the raw MASCOT data to find samples that were differentially detected in
the experimental and control samples. Exclusions were made based on relative
abundance in the control samples, repositories of known contaminants, and subcellular
location, as a result of the prerequisite fractionation (Mellacheruvu 2013). Manual
curation relied heavily on the UniProt database though several cases required rigorous
searches of the literature to determine protein function, possible validity, and
relevance (Apweiler 2004).
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CHAPTER 3

RESULTS

FANCD2 Interacting Proteins can be Detected by Mass Spectrometry.
To determine if the system was workable, several pulldowns were performed
to enrich for FANCD2 immune complexes.

Using a commercially available V5

antibody it was possible to enrich for both FANCD2 and monoubiquitinated FANCD2
(Figure 1). The remaining eluate from the immunoprecipitation did not present a
differential banding pattern when stained (Figure 2). Lack of visual detection does not
preclude detectable differences between samples, so gel pieces from the SDS-PAGE
were excised and examined by mass spectrometry. The mass spectrometry results
confirmed the presence of FANCD2, however it did not identify any strong candidates
for further analysis (Table 1).
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Figure 1. Immunoblot of FANCD2 immunoprecipitation
PD20 patient cells containing empty vector or corrected with FANCD2-V56xHis (D2-V5/6xHis) were grown to confluency and half the cells were treated with
250 nM MMC for 16 hours. Cells were harvested following treatment and then lysed
in NETN300 (20 mM Tris-HCl, 300 mM NaCl, 1 mM EDTA, 1 mM Na3O4V, 1 mM
NaF, Roche protease inhibitor cocktail tablet). 1 mg of cellular extract was used for
the immunoprecipitation which was supplemented with NETN100 to make a 1 mL
sample. The samples were not subjected to the pre-clearing step. The commercially
available V5 antibody was allowed to incubate with the sample overnight. 30 µg of
cell extract was run in the first four lanes of a 3-8% Tris-Acetate gel as a control while
5 µL of the 40 µL eluate was loaded into the last four lanes to probe the success of the
IP. The SDS-PAGE was performed and followed by the immunoblotting protocol. The
blot was probed with the FANCD2 (NB100-182, Novus Biologicals) antibody
showing that the IP was able to enrich for FANCD2 as seen in lane seven and eight.
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Figure 2. Coomassie stain of the FANCD2 immunoprecipitation
35 µL of the 40 µL of eluate described in Figure 1 were resolved by SDSPAGE on a 3-8% Tris-Acetate gel then stained with the SimplyBlue SafeStain
(LC6060, Invitrogen). The gel does not show any bands that are more prominent in the
corrected line than in the hypomorphic line. Taken together with the results from the
immunoblot it would suggest that the amount of differential protein present in the
eluate is not above the threshold for detection using the coomassie reagent. A 1 mm
wide vertical strip spanning the length of the gel was excised from lane two and lane
four. The vertical strips were each separated into twelve 1 cm long pieces. These 1 cm
long strips were cut into pieces no larger than 2 mm3. Samples underwent preparation
for mass spectrometry as described in the materials and methods section and were
submitted for analysis by mass spectrometry. The results from lane two were used to
remove any nonspecific interactions that were pulled down with the beads appearing
in lane four.
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Table 1. Mass spectrometry results from PD20 FANCD2-V5/6xHis V5 IP
These results were analyzed using ProteoIQ version 2.2. All results were
subjected to a 5% false discovery rate validation. Proteins which were detected in the
empty sample were removed from the proteins that were present in the V5 IP. Only
ten proteins were validated using this method. The most prominent of the detected
proteins was FANCD2 confirming the success of the IP. The other proteins that were
detected registered very few spectral counts. Apart from the low rate of detection for
these proteins several of the proteins are cytoplasmic or secreted and therefore are not
likely to be involved or affected by the chromatin targeting of FANCD2.
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Protein
BBX
ENO2
FANCD2
FLJ59433
MYH1
RPSAP58
S100-A14
TRIM35
TUBA1A
YBX1

Function
HMG box transcription factor
Maintains and protects neurons
Required for chromosomal stability
Translation elongation factor
Muscle contraction
Ribosome constituent
Modulates p53 protein levels
Possible Tumor Suppressor
Cytoskeletal protein
Regulation of transcription
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pLenti 6.2 FANCD2-V5 is Functionally Incorporated into the Cell
Using the pLenti FANCD2-V5 vector to correct the cells shows a functional
incorporation of the protein into the cellular machinery. The FANCD2-V5 undergoes
ubiquitination following exposure to MMC (Figure 3) and is also localized to
chromatin (Figure 4). To adequately correct the sensitivity to crosslinking agents
FANCD2 must undergo monoubiquitination, chromatin localization, and discrete
nuclear foci formation. Monoubiquitination demonstrates that the protein is at least
interacting with the components of the core complex which ubiquitinate the protein.
Chromatin localization places the protein in the context of DNA repair and in
proximity with other DNA repair proteins. The ability to enrich activated chromatin
associated FANCD2 allows for specific screening of interaction occurring in the
context of an active DNA repair environment. The incorporated protein can be
targeted by the commercial V5 antibody for enrichment, and should function as a
useful platform to detect proteins that interact with activated FANCD2 in the context
of DNA repair.
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Figure 3. pLenti 6.2 FANCD2-V5 is efficiently ubiquitinated following exposure
to crosslinking agents
PD20 cells stably corrected with pLenti 6.2 FANCD2-V5 and a control line
with stably incorporated pLenti 6.2 LacZ-V5 were grown to confluency and half of the
cells were treated with 250 nM MMC for 16 hours. The cells were harvested and lysed
in 2% SDS lysis buffer. The whole cell lysate was quantified using the BCA assay and
samples were normalized to 30 µg than resolved by SDS-PAGE followed by
immunoblotting with a V5 antibody. The immunoblot clearly shows an induction of
monoubiquitinated FANCD2 following MMC treatment in the corrected line. This
indicates that a sizeable portion of the FANCD2 that is expressed is functionally
incorporated into the cell.
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Figure 4. pLenti 6.2 FANCD2-V5 is localized to chromatin following exposure to
crosslinking agents
PD20 cells stably corrected with pLenti 6.2 FANCD2-V5 and a control line
with stably incorporated pLenti 6.2 LacZ-V5 were grown to confluency and half of the
cells were treated with 250 nM MMC for 16 hours. The cells were fractionated as
described using the CSK buffer and NRB with micrococcal nuclease. The IP was
performed using a V5 antibody with the chromatin associated fraction.
Immunoblotting with FANCD2 shows the effect of enrichment by the fractionation
and the immunoprecipitation. Lanes one through four show the soluable fraction
which has a large proportion of the nonubiquitinated FANCD2. Lanes five through
eight show the Chromatin associated fraction which as a clear enrichment for
monoubiquitinated FANCD2. The nonubiquitinated form is able to associate with
chromatin but at a much lower frequency possibly suggesting that monoubiquitination
stabilizes the association. Lanes nine through twelve show that the IP is able to pull
down the monoubiquitinated FANCD2 from the chromatin associated fraction. The
H2A immunoblot demonstrates that the fractionation was specific for chromatin
associated proteins. Histones are normally very tightly bound to DNA in the
nucleosome, as expected H2A is absent from the soluble fraction but present in the
chromatin associated fraction.
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Fractionation Allows Isolation of FANCD2 Immune Complex Members from
Endogenous Systems
Isolating the chromatin associated portion of cells has shown to enrich
activated FANCD2. However the fractionation method required large volumes of cells
to generate large enough protein volumes to successfully IP from. Using transformed
cells such as HeLa cells allows for the rapid generation of large volumes of high
protein content cells. Using unmodified HeLa cells removes the option to pull down
using the V5 epitope tag. The cells were fractionated and then underwent a FANCD2
IP using an antibody against FANCD2 to enrich for FANCD2 immune complexes
(Figure 5). The eluate was resolved by SDS-PAGE and stained to observe differential
banding patterns which could be excised and submitted for analysis by mass
spectrometry (Figure 6). The analysis revealed a number of functionally diverse
candidates with varying detection strengths (Table 2). One of the difficulties with the
endogenous system is the lack of specificity with the antibody used. The best available
antibody for FANCD2 has multiple targets within the cell. The issue of nonspecific
binding is exacerbated by the PIS control which also binds several proteins
nonspecifically and may invalidate or mask interacting partners. While the HeLa
system is able to identify several candidates the large amount of contaminants and
nonspecific interactions in the data demonstrate the need for a more sensitive system
to screen for interacting proteins.
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Figure 5. Enrichment of FANCD2 from HeLa cells using FANCD2
immunoprecipitation
HeLa cells were grown to confluency and half were treated with 250 nM MMC
for sixteen hours. The cells were fractionated using CSK buffer and NRB
supplemented with micrococcal nuclease. 1 mg of the chromatin associated fraction
was incubated with a FANCD2 antibody (NB100-182, Novus Biologicals) and pulled
down using magnetic beads. The sample was also incubated with rabbit pre immune
serum and magnetic beads as well as just the magnetic beads. Only the MMC treated
The IPs are shown in the blot above as they were the only samples to be submitted to
proteomic analysis. The immunoblot for FANCD2 (sc-20022, Santa Cruz)
demonstrates that monoubiquitinated chromatin associated FANCD2 is present in the
FANCD2 IP and is not pulled down nonspecifically by rabbit serum or the magnetic
beads. The Immunoblot for H4 shows that the chromatin fractionation was successful.
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Figure 6. Silver stain of FANCD2 immune complexes from HeLa cell chromatin
fractions
The remaining eluates from the IP in Figure 5 were resolved by SDS-PAGE
then were stained with the mass spectrometry compatible silver stain kit. The gel
contains the eluates of the bead pull down, the pre immune serum (PIS) pull down,
and the FANCD2 pull down. The silver stain shows nine differentially staining
regions in the gel between the PIS and FANCD2 pull downs. The nine regions
indicated were excised from both lanes of the gel so that nonspecific interaction could
be removed from the FANCD2 IP results. The bands were excised as fragments
approximately 1 mm tall and 1 cm wide which were subsequently cut into
approximately 1 mm3 cubes. The bands were distained were than subjected to the
tryptic in gel digestion protocol. The six most prominent bands were submitted for
mass spectrometry analysis.

29

30

Table 2. Abridged list of candidates identified from HeLa FANCD2 immune
complexes
These results were analyzed using ProteoIQ version 2.2. All results were
subjected to a 5% false discovery rate validation. Proteins which were detected in the
pre immune serum sample were removed from the proteins that were present in the
FANCD2 IP. Using the Uniprot database Proteins that were detected that are found
solely in the cytoplasm or extra cellular matrix of the cell were deemed as nonspecific
because of the prefractionation before the IP which should have removed these
interactions (Apweiler 2004). While working in a biosaftey cabinet and taking care to
wipe all surfaces and instruments down with ultrapure water, it is still not possible to
remove all environmental contamination. Several candidates were identified with this
screen and not all positive results are displayed on this list. While several candidates
have a significant number of spectral counts there are still many which have very few
spectral counts. Candidates detected hail from a diverse functional background.

31

Protein
ADAR
AZI1
CCAR1
CEP135
DHX29
DHX30
DHX9
FANCD2
LRPPRC
MYBBP1A
NUP155
NUP160
RBM6
SF3B1
SIN3B
SMC3
STAG1
SUGP2
TP63

Function
RNA processing
Centrosomal protein
Functions as a p53 coactivator
Involved in centriole biogenesis
ATP-binding RNA helicase
Interacts with DNA and SSBP1
Unwinds DNA and RNA
Required for chromosomal stability
Binds to poly(A) mRNAs
May activate or repress transcription
Component of nuclear pore complex
Involved in poly(A)+ RNA transport
Binds poly(G) RNA homopolymers
Identified in spliceosome C complex
Acts as a transcriptional repressor
Required for chromosome cohesion
Component of cohesin complex
May play a role in mRNA splicing
transcriptional activator or repressor
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Large Scale Enrichment of FANCD2 Immune Complexes from PD20 Patient
Cells Identifies Several Interacting Candidates
Previous work with the PD20 patient cells showed it was difficult to generate a
large enough volume of the chromatin associated fraction to be able to enrich enough
FANCD2 immune complexes to detect by silver stain. Large volumes of cells were
cultured to perform fractionations and subsequent IPs on. The process was shown to
enrich for chromatin associated monoubiquitinated FANCD2 (Figure 7). The silver
stain showed sixteen detectable differential bands or regions between the IP samples
which were analyzed by mass spectrometry (Figure 8). The mass spectrometry
analysis revealed several candidate proteins, which have been broken down into six
different groups which includes nucleosome remodeling, nuclear matrix, DNA repair,
transcription regulation, chromosome maintenance, and a miscellaneous proteins
group (Table 3-8). All of these tables were generated using ProteoIQ 2.2 analysis. All
results were subjected to a 5% false discovery rate validation. Proteins that were
detected that are found solely in the cytoplasm or extra cellular matrix of the cell were
deemed as nonspecific because of the prefractionation before the IP which should
have removed these interactions. Common contaminants of this method were detected
and removed from candidate lists. Immune complex candidate proteins which were
detected at an equal or higher rate in the sample lacking any V5 epitope were removed
from the list and seen as a nonspecific interaction.
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Figure 7. Enrichment of chromatin associated monoubiquitinated FANCD2 from
PD20 patient cells
PD20 empty and PD20 pLenti 6.2 FANCD2-V5 cells were each plated into
sixty four 15 cm dishes and grown to confluency. All of the cells were treated with
250 nM MMC for 16 hours and subsequently harvested. The cell pellets were
fractionated using the CSK buffer to extract the soluable fraction (S) and ATM lysis
buffer with benzonase to extract the chromatin associated fraction (C). 5.2 mg of the
chromatin fraction was incubated with the V5 agarose beads to pull down FANCD2V5 immune complexes. The complexes were resolved by SDS-PAGE alongside 10 µg
amounts of the cellular fractions to be used as controls. Immunoblotting with H3
demonstrates the success of the fractionation and the FANCD2 immunoblot shows
that FANCD2 was pulled down during the immunoprecipitation.
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Figure 8. Silver stain of FANCD2 immune complexes from the PD20 cell
chromatin fraction
The remaining eluates from the IP in Figure 7 were resolved by SDS-PAGE
than was stained with the mass spectrometry compatible silver stain kit. The gel shows
two lanes of 10 µgs of the raw chromatin associated fraction in addition to the two V5
IP eluates. The silver stain shows sixteen differentially staining regions in the gel
between the PD20 empty and the PD20 FANCD2-V5 pull downs. The sixteen regions
indicated were excised from both lanes of the gel so that nonspecific interaction could
be removed from the FANCD2 IP results. The bands were excised as fragments
approximately 1 mm tall and 1 cm wide which were subsequently cut into
approximately 1 mm3 cubes. The bands were distained then subjected to the tryptic in
gel digestion protocol. It should be noted that bands do not necessarily indicate the
presence of a single discrete protein but are simply an abundance of protein above the
threshold for detection. Several different protein co-migrating may contribute to the
overall concentration of proteins possibly causing large smeared bands or regions with
various detectable proteins. To reduce the problem of protein contamination work was
performed in a biosaftey cabinet and care was taken to wipe all surfaces and
instruments down with ultrapure water. The gel was also wrapped in saran wrap to
prevent exposure to additional sources of contamination while it was being imaged,
resulting in several observable distortions in the captured image of the gel.
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Table 3. Nucleosome remodeling proteins in FANCD2-V5 immune complexes
This table shows the candidates that were identified as nucleosome remodeling
components. Numerous remodeling complex members were identified including the
ASAP, BAF, FACT, and NuRD complexes. Also grouped in with this category are the
histone proteins that were detected. It is difficult to identify the histone variants with
the methods that were used in this screen so the variants represented in the table are
reflection of the inherent uncertainty in different isoforms and postranslation
modifications. More detailed analysis of histone members would require special
proteomic techniques and parameters.
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Protein
ACIN1
ANP32B
BAG6
BRD3
CDC73
FBL
H1F0
H1FX
H2AFJ
HIST1H1B
HIST1H1C
HIST1H1D
HIST1H2AD
HIST1H2BK
HIST1H2BL
HIST1H2BN
HIST1H4H
HIST2H3A
KIF11
NAT10
PHB2
RELA
SAP18
SMARCA4
SMARCA5
SMARCB1
SMARCC2
SNF2L1
SUPT16H
TRIM28

Function
Component of ASAP complex
apoptosis and splicing complex
Cell cycling nucleasome chaperone
Chaperone involved in p53 activity
and chromatin regulation H3K4me2
Binds actlyated histones
Transcription regulation nucleosome
remodeling complex H3 methylation
Histone methyl transferase
H2AQ104me
Histone H1
Histone H1
Histone H2A
Histone H1
Histone H1
Histone H1
Histone H2A
Histone H2B
Histone H2B
Histone H2B
Histone H4
Histone H3
Component of large chromatin
remodeling complex
Able to actylate histones
HDAC recruitment
Transcriptional regulator with
DDX1 interacts with HDACs
Nucleosome remodeling
transcription
Component of the BAF chromatin
remodeling complex
Helicase with nucleosome
remodeling activity
Chromatin remodeling
Chromatin remodeling for
transcriptional activation/repression
Nucleosome remodeling factor
Nucleosome reorganizer
Recruits NuRD degrades p53
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Table 4. Nuclear matrix proteins in FANCD2-V5 immune complexes
The nuclear matrix proteins identified largely fall into two groups relating to
the nuclear envelope. The Lamin proteins were detected with high spectral counts but
were also somewhat abundant in the control sample, though there is a clear increase in
the number of spectra detected in the V5 sample. The other large group relates to the
nuclear pore complex. Several nuclear pore proteins were identified in the screen and
in past screens which has been previously published on (Boisvert 2013).
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Protein
FNBP3
LMNA
LMNB1
LMNB2
NUP107
NUP188
NUP93
ODF2
RANBP2

Function
Nuclear matrix
Nuclear membrane chromatin
interacting
Nuclear membrane chromatin
interacting
Nuclear membrane chromatin
interacting
Nuclear pore complex
Component of nuclear pore complex
Nuclear pore complex
Centrosome matrix required for
localizing PLK1
E3 for SUMO of UBE2I component
of nuclear pore complex required for
export
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Table 5. DNA repair proteins in FANCD2-V5 immune complexes
DNA repair proteins identified in the screen are listed in the table above. While
many of the proteins in this list are familiar to the FA pathway very few have a highly
enrich spectral count in the V5 sample. While it is welcoming to see known FANCD2
interacting proteins such as PCNA in the screen the strongest candidates identified in
this group are VCP and SFPQ (Howlett 2009). These proteins may have a direct role
in recruiting FANCD2 to sites of DNA damage.
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Protein
ASCC3
DDX1
ILF2
PARP1

PCNA
PSMD1
REV1
SFPQ
VCP

Function
3'-5' DNA helicase involved in
repair of alkylated DNA
RNA clearance at DNA DSB
Stabilizes Ku70/Ku80
Base excision repair chromatin
architecture required for PARP9 and
53BP1 recruitment
TLS
Regulatory subunit of proteasome
DNA repair
Nucleotide binding may be involved
in ss invasion and NHEJ
Recruited to stalled replication forks
by SPRTN Recruits 53BP1
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Table 6. Transcription regulation proteins in FANCD2-V5 immune complexes
A large number of proteins involved in the regulation of transcription were
identified. These proteins are involved in both transcriptional activation and
repression. With FANCD2 being implicated in transcriptional regulation it makes
sense that it would interact with other transcription proteins (Park 2013). Many of the
transcription factors identified hail from different functional backgrounds and do not
readily divide into groups or complexes.
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Protein
AIMP2
ALYREF
ATAD2
BTF3
CHCHD3
CSNK2A1
CTNNB1
CTNND1
DDX17
DDX3X
DDX3Y
DDX5
FHL2
FLII

GAPDH
HELZ2
HMGA1
HMGN4
HNRPK
MYBBP1A
NF2
PELP1

RPB1
RPB2
SAFB2
SND1
SNW1
STAU1

Function
Empty spectra
Prevents p53 degredation
1
mRNA transport THO complex
0
component
Transcriptional coactivator of ESR1
1
Transcription
2
BAG1 repressor
0
Cell signaling apoptosis
0
transcription
Negative regulator of chromosome
0
cohesion
Catennin Wnt signaling
1
Helicase transcriptional regulation
10
Transcription regulation
7
ATP dependant RNA helicase
5
Transcritiptional coactivator p53
15
RUNX2
Transcription regulation
0
May be a transcriptional coactivator
1
associated with hormone activated
nuclear receptors
Carbohydrate degredation apoptosis
8
Interacts with and coactivates
0
PPARA and PPARG
Transcription regulation
0
chromatin
0
Interacts with p53 and p21 necessary
1
for apoptosis
Transcriptional activator or
2
repressor
Tumor supression
0
Coactivator of ER transcription
0
corepressor of other hormone
receptor transcription
DNA dependant RNA polymerase
0
component of RNA pol II
Component of RNA pol II
2
Binds matrix attachment region
1
DNA estrogen receptor corepressor
Transcriptional and p100 coactivator
0
Transcriptional regulation and
2
mRNA splicing p53 interacting
DNA binding
1
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Table 7. Chromosome maintenance proteins in FANCD2-V5 immune complexes
A large amount of proteins involved in chromosomal maintenance were
identified in the screen. Multiple members of many groups were identified such as,
centrosomal proteins, spindle proteins, replication initiation, cohesin, and condensin.
Two of the MCM proteins identified in the screen have recently been shown to
interact with FANCD2 (Lossaint 2013). Nearly all of the SMC proteins were
identified in the screen which implicates FANCD2 interacting with cohesin,
condensin, and the SMC5-SMC6 complex. The large number of centrosomal proteins
detected in the screen also suggests an interaction between FANCD2 and the
centrosome.
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Protein
AKAP8L
AURKB

Function
Empty spectra
Chromatin condensation
1
Regulates chromosome alignment and
1
stability as well as p53
AZI1
Centrosome
0
CDC42
Apoptosis transcription Spindle
0
CDK1
Regulates cell and centrosome cycling
2
CEP135
Centrosomal protein centriole biogenesis
0
CEP250
Important role in centrosome cohesion
0
CKAP2
P53 dependant cell cycle regulator
0
DYNC1LI1
Chromosome migration
0
HAUS3
Centrosome integrity
1
HAUS6
Spindle assembly interacts with PLK1
0
LZTS2
Centrosome and Wnt signaling
0
MCM5
DNA replication initiation
0
MCM7
DNA replication initiation
0
NCAPD2
Component of condensin I complex
0
NDC80
Chromosome segregation
0
NEK7
Centrosome spindle formation
0
NUDCD2
Centrosome
0
NUMA1
Involved in teathering centrosome to
12
tubulin and spindle assembly
PCM1
Required for centrosome assembly and
2
function interacts with CEP 250
PDS5
Regulator of sister chromatid cohesion
0
during mitosis
PPP1CA
Chromatin structure
1
PPP1CB
Regulates chromatin structure
0
PPP2CB
Centrosome spindle
0
PPP2R1A
Chromosome segregation
0
SLC25A5
Chromosome segregation
1
SMC1A
Involved in chromosome cohesion during
0
cell cycle and damage BRCA1 interactor
SMC2
Component of condensing complex
2
SMC3
Required for chromosome cohesion
4
SMC4
Component of condensin complex
1
SMC6
Involved in dsDNA break HRR
0
SPAG5
Required for normal chromosome
0
segregation
TNKS1BP Binds TNKS1 and TNKS2 colocalizes
0
with chromosomes during mitosis
TOP1
Cuts one strand of DNA during
1
replication and transcription
TOP2A
DNA topoisomerase 2 Makes DNA ds
0
breaks required for mitotic segregation
47

V5 spectra
6
2
3
2
7
2
3
3
2
2
3
1
4
4
6
1
2
1
31
14
7
4
3
2
4
26
19
12
24
12
5
3
3
9
10

Table 8. Other candidate proteins in FANCD2-V5 immune complexes
The remaining proteins identified in the screen are mostly involved in nuclear
import and ubiquitination. Several nuclear import proteins were identified however, it
is unclear how these proteins interact with chromatin associated FANCD2. Ubiquitin
was strongly enriched in the V5 sample however this ubiquitin could be a result of the
monoubiquitination of FANCD2. With the experimental design the program has no
way of determining the origin of ubiquitin in the sample and it is highly possible that
the ubiquitin was cleaved off of FANCD2 or any of the other ubiquitinated proteins in
the pathway. The analysis did not include searching for diglycine modifications
indicating protein ubiquitination, so it is also unknown which proteins in the sample
were ubiquitinated.
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Protein
IPO5
IPO9
KPNB1
TNPO1
UBC
USP5

Function
Nuclear import
Nuclear protein import
Nuclear import
Nuclear transport histones
Ubiquitin
Degrades K48 ubiquitin linkages
causes accumulation of p53 (Dayal
2009)
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Validating Structural Maintenance of Chromosomes Candidates
One of the strongest groups of candidates from the mass spectrometry screen
was the structural maintenance of chromosomes proteins. SMC1A, SMC2, SMC3,
SMC4 and SMC6 were detected in the large scale patient cell IP (Table 7). SMC3 was
also detected in the endogenous IP system (Table 2). SMC1 and SMC3 are
component of the cohesin complex along with STAG1 which was detected in the
endogenous system (Table 2). The cohesin complex sister chromatids together which
allows for the identification of sister chromatids (Rudra 2013). SMC2 and SMC4 are
members of the condensing complex. CAPD2 is also a member of condensin which
was detected in the PD20 patient screen (Table 7). The condensin complex is required
for the proper condensation and segregation of chromosomes (Hirano 2012). The
SMC5-SMC6 complex plays a role in DNA damage repair though this may be
mediated through cohesin recruitment (Potts 2006). Components of these complexes
were detected in the FANCD2 immune complexes by immunoblotting (Figure 9). The
input in Figure 9 shows that there may be less SMC protein expressed in FANCD2
hypomorphic cells following exposure to MMC, however expression of these proteins
does not apper to be largely affected by FANCD2 or MMC (Figure 10). The dynamic
of the interaction

between

FANCD2

and

these proteins

require further

characterization. Because these proteins are involved in genomic stability it is possible
that these proteins may have some overlapping functions with maintaining genomic
stability. Using MAGI to query the cancer genome atlas shows that mutations in both
the cohesin (5.96%) and condensin (5.42%) networks are common in cancer.
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Figure 9. Structural maintenance of chromosomes proteins are present in
FANCD2 immune complexes
PD20 empty and PD20 pLenti 6.2 FANCD2-V5 cells were treated with 250
nM MMC for 16 hours and subsequently harvested. The cell pellets were fractionated
using the CSK buffer to extract the soluable fraction and ATM lysis buffer with
benzonase to extract the chromatin associated fraction. The chromatin fraction was
incubated with the V5 agarose beads to pull down FANCD2-V5 immune complexes.
The complexes were resolved by SDS-PAGE alongside 10 µg amounts of the
chromatin fractions to be used as controls. Immunoblotting with the antibodies shown
demonstrates that SMC1A, SMC4, SMC6, CAPD2 and CAPD3 are all present in
FANCD2 immune complexes. These proteins represent cohesin, condensin-I,
condensin-II, and the SMC5-SMC6 complex.
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Figure 10. Structural maintenance of chromosomes proteins expression in PD20
patient cells
PD20 pLenti 6.2 LacZ-V5 and PD20 pLenti 6.2 FANCD2-V5 cells were
treated with different doses of MMC (0nM, 50nM, 100nM, 250nM) for 16 hours and
subsequently harvested. The cell pellets were lysed in 2% SDS lysis buffer to survey
total levels of cellular expression. 30 µg of the lysate was loaded into a gel and then
resolved by SDS-PAGE. Immunoblotting with the antibodies shown demonstrates that
SMC1A, SMC4, SMC6, CAPD2 and CAPD3 are all present in both corrected cells
and cells with hypomorphic FANCD2 expression. The profile also shows that the
proteins are not grossly affected by the presence of MMC within the cell. This result
excludes the possibility that the association is caused by increased expression of
structural maintenance of chromosomes proteins within the cells following MMC
exposure.
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FANCD2 may Interact with Components of the SWI/SNF Complex
Several SWI/SNF proteins were also identified in the mass spectrometry
screen. SMARCA4, SMARCA5, SMARCB1, and SMARCC2 were all identified in
the patient cells as members of FANCD2 immune complexes along with several other
nucleosome remodeling proteins (Table 3). Among the other proteins discovered was
SUPT16H which is known to interact with SWI/SNF proteins in complexes (Table 3).
The SWI/SNF proteins are important for transcriptional regulation, determination of
cellular fate, and tumor suppression (Lu 2013). Using MAGI to query the cancer
genome atlas shows that mutations in the SWI/SNF network are very common in
cancer (16.14%). Using inducible knockdown cells for SWI/SNF components it was
demonstrated that FANCD2 expression is affected by knockdown of SWI/SNF
components (Figure 11). The relationship that SWI/SNF proteins have with FANCD2
may be more related to the canonical function of SWI/SNF proteins as chromatin
remodelers and transcription regulators. It is possible that the interaction between
FANCD2 and SWI/SNF proteins may be upstream of transcription or it may be
involved in stabilizing FANCD2 protein levels.
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Figure 11. SWI/SNF knockdown does not affect FANCD2 monoubiquitination
The MCF10A cells used have a stably integrated cassette, which expresses a
shRNA and GFP in the presence of doxycycline. The different cells have different
knockdown targets, SMARCA2/BRM, SMARCA4/BRG1, and a scrambled shRNA
which has no target. The cells were treated with 0.01 µg/mL of doxycycline for 72
hours. During the final 24 hours of doxycycline treatment the cells were co-treated
with 200 nM MMC. The cells were harvested and lysed with 2% SDS lysis buffer to
extract the proteins from the cells. 30 µg of cell lysate was loaded into gels to be
resolved by SDS-PAGE and subsequent immunoblotting. The cell were probed for
GFP to assess if the shRNA was expressed, GFP expression in this case is a proxy for
knockdown. The samples were also probed for FANCD2 to determine if knockdown
of SWI/SNF component would impede the ubiquitination and therefore activation of
the FA pathway. In the MCF10A cells used FANCD2 undergoes a normal
ubiquitination response to MMC both with and without doxycycline mediated
knockdown.
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CHAPTER 4

DISCUSSION

Identifying FANCD2 Interacting Candidate Proteins
Using mass spectrometry to identify novel interacting partners has been a
challenging and rewarding technique. There are many difficulties in working with a
large low abundance protein, but the data generated from the mass spectrometry
screen has shown many new interesting results. The technique was also able to detect
some already known interactions such as PCNA (Table 5, Howlett 2009) and the
MCM proteins (Table 7, Lossaint 2013). Developing a method which is able to pull
down chromatin associated FANCD2 immune complexes to detect by mass
spectrometry has opened the door for similar IP based experiments.
The screen has identified several candidates from diverse functional groups
which may indicate a larger functional role for FANCD2 and the FA-BRCA pathway.
The numerous strong candidates identified by this method will require subsequent
validation and characterization. This process has been started on several proteins
however the large volume of data will require a systematic and methodical approach to
utilize the data generated from the screen. The unbiased nature of the screen also does
not discriminate against upstream or downstream proteins and does not occlude subtle
events. Upstream events can be easily assayed by looking at FACND2
monoubiquitination, chromatin localization, and nuclear foci formation, in response to
interstrand crosslinking agents which are all well developed assays within the lab.
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Genomic instability can be assayed through metaphase spreads to determine if a
protein interaction is involved in promoting repair downstream of FANCD2. But the
need for new methods may be most realized while investigating subtle effects, which
may only be viewable during specific conditions, or may require more information
from experiments than is currently recorded as data. As more is known about
FANCD2 it is increasingly likely that newly identified interacting proteins may have a
less visible effect on the cell, but that does not bar these new interactors from playing
a profound or underappreciated role within the pathway.

FANCD2 may Interact with the Structural Maintenance of Chromosomes
Proteins
The mass spectrometry data show a strong likelihood that FANCD2 is
involved with the structural maintenance of chromosomes proteins in some way.
SMC3 is one of the few proteins that were detected in both the endogenous and patient
systems (Table2, Table 7). Cohesin has been shown to be enriched at sites of stalled
forks and the SMC proteins SMC1A, SMC3, SMC4, SMC5, and STAG2, have
previously been detected as FANCD2 interacting candidates (Lossaint 2013).
Knockdown for FA proteins and SMC proteins share a genomic instability and
improper segregation phenotype (Nalepa 2014, Hirano 2012). With the connection to
genomic instability the cohesin and condensin complexes as well as the SMC5-SMC6
complex make excellent potential candidates for FANCD2 interactors. These proteins
are also highly involved in chromatin architecture restructuring which may be a
critical component to understanding how the FA-BRCA pathway becomes activated
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upon damage detection. While the SMC proteins have been implicated in DNA repair
the mechanism by which they act to repair DNA is currently unknown.

FANCD2 may Interact with the SWI/SNF Proteins
The SWI/SNF proteins are known as both nucleosome remodelers and
transcription factors (Lu 2013). As a known tumor suppressor and the large number of
complex members identified (Table 3), the SWI/SNF proteins make strong candidates
for evaluation. The affect that the SWI/SNF proteins have on FANCD2 protein levels
may be of great importance and it may provide a mechanism by which the SWI/SNF
cells act as tumor suppressors. It is important to continue to evaluate the relationship
between FANCD2 and the SWI/SNF proteins. There are still many metrics for
characterization to look at such as chromatin localization and FANCD2 nuclear foci
formation.

FANCD2 and Histones
Another notable interaction identified by this study is the interaction between
FANCD2 and histones. Several histone variants were identified as the candidates
however it is difficult to determine the strength of this interaction as the peptides also
showed several spectral counts in the control sample, albeit at a lower frequency
(Table 3). There are several possible reasons for this perceived interaction with
histones, it may be an indirect interaction between nucleosome remodeling proteins
that interact with FANCD2 or it may be an artifact of FANCD2 associating with
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chromatin. However this does not preclude the possibility that FANCD2 may be
directly interacting with histones.
The idea that FANCD2 may be interacting with histone is supported by the
premise that FANCD2 acts as a histone chaperone (Sato 2012). This idea is further
evidenced by the discovery of a possible histone binding domain within FANCD2
(unpublished data). With the difference in some of the histone peptides detected in this
experiment exceeding a fourfold change in some cases it is reasonable to believe that
chromatin associated FANCD2 may have a direct interaction with histones.
Enrichment is shown for Histone H1, Histone H2A, Histone H2B, Histone H3, and
Histone H4 (Table 3). It is important to realize that DNA repair occurs within the
context of chromatin and while detecting interactions with histones the abundance of
posttranslational modifications and histone variants remains unknown and is not likely
to be decoded with such a broad screening method.
The diversity and prevalence of histones and histone remodeling proteins
within the data allude to the idea that FANCD2 may be involved in binding specific
chromatin marks or in causing changes in the profile of chromatin modifications. The
FA-BRCA pathway may be regulated by the histone code or alternatively may be
actively involved in writing the histone code. With several of the proteins in the FA
core complex being understudied it is possible that the FA core complex along with
FANCD2 may have a role in recognizing and modifying structures in chromatin either
is conjunction with or separate from the ability for the FA-BRCA pathway to promote
repair of the highly genotoxic ICL lesions.
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Conclusions
This project has demonstrated a successful method to enrich for chromatin
associated active FANCD2 immune complexes, and has given large clues as to which
proteins compose the activated FANCD2 immune complexes. While this data shows a
dramatic increase in the information known about possible FANCD2 interacting
proteins, the data still requires a great deal of investigation to be performed. The
methods and data described here show the massive power associated with proteomics
techniques. The discovery of several strong candidate interacting proteins as well as
preliminary data to characterize the interaction should contribute to understanding the
activity and regulation of FANCD2 and the larger FA-BRCA pathway function in a
meaningful way. Hopefully the information generated in the screen can contribute to
the improvement for healthcare options of FA patients and increase the understanding
of how DNA repair is mediated within the cell.
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